Seremba E, Van Geertruyden J P, Ssenyonga R, Opio C K, Kaducu J M, Sempa J B, Colebunders R, Ocama P
Department of Medicine, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Global Health Institute, University of Antwerp, Belgium.
Vaccine. 2017 May 19;35(22):2937-2942. doi: 10.1016/j.vaccine.2017.04.020. Epub 2017 Apr 20.
Hepatitis B (HBV) in sub-Saharan Africa is believed to be horizontally acquired. However, because of the high HBV prevalence in northern Uganda, no hepatitis B vaccination at birth and no access to HBV immunoglobulin, we hypothesize that vertical transmission also could also play an important role. We therefore investigated the incidence of HBV among babies presenting for their first HBV vaccine dose in Gulu, Uganda.
We recruited mothers and their babies (at least 6-week old) presenting for their postnatal care and first HBV vaccine dose respectively. Socio-demographic and risk factors for HBV transmission were recorded. Mothers were tested for Hepatitis B core antibody (anti-HBc-IgG) and hepatitis B surface antigen (HBsAg). HBsAg-positive sera were tested for hepatitis B e antigen (HBeAg) and HBV viral load (HBVDNA). Babies were tested for HBsAg at presentation and at the last immunization visit. A sample of HBsAg-negative babies were tested for HBVDNA. Incident HBV infection was defined by either a positive HBsAg or HBVDNA test. Chi-square or fisher's exact tests were utilized to investigate associations and t-tests or Wilcoxon rank-sum test for continuous differences.
We recruited 612 mothers, median age 23years (IQR 20-28). 53 (8.7%) were HBsAg-positive and 339 (61.5%) were anti-HBc-IgG-positive. Ten (18.9%) of the HBsAg-positive mothers were HBeAg-positive. Median HBVDNA levels of HBV-infected mothers was 5.7log (IQR 4.6-7.0) IU/mL with 9 (17.6%) having levels≥10IU/mL. Eighty (13.3%) mothers were HIV-infected of whom 9 (11.5%) were co-infected with HBV. No baby tested HBsAg or HBVDNA positive.
Vertical transmission does not seem to contribute substantially to the high HBV endemicity in northern Uganda. The current practice of administering the first HBV vaccine to babies in Uganda at six weeks of age may be adequate in control of HBV transmission.
在撒哈拉以南非洲地区,人们认为乙型肝炎(HBV)是通过水平传播获得的。然而,由于乌干达北部地区HBV感染率很高,且未实施出生时乙肝疫苗接种以及无法获得乙肝免疫球蛋白,我们推测垂直传播可能也起着重要作用。因此,我们调查了乌干达古卢地区首次接种乙肝疫苗的婴儿中HBV的感染率。
我们分别招募了前来接受产后护理的母亲及其婴儿(至少6周龄),并为婴儿接种首剂乙肝疫苗。记录了社会人口统计学和HBV传播的风险因素。对母亲进行了乙肝核心抗体(抗-HBc-IgG)和乙肝表面抗原(HBsAg)检测。对HBsAg阳性血清进行了乙肝e抗原(HBeAg)和HBV病毒载量(HBVDNA)检测。在婴儿就诊时和最后一次免疫接种时对其进行HBsAg检测。对一部分HBsAg阴性婴儿进行了HBVDNA检测。HBV感染新发病例定义为HBsAg或HBVDNA检测呈阳性。采用卡方检验或费舍尔精确检验来研究关联性,采用t检验或威尔科克森秩和检验来分析连续变量差异。
我们招募了612名母亲,中位年龄23岁(四分位间距20 - 28岁)。53名(8.7%)母亲HBsAg呈阳性,339名(61.5%)母亲抗-HBc-IgG呈阳性。10名(18.9%)HBsAg阳性母亲HBeAg呈阳性。HBV感染母亲的HBVDNA中位水平为5.7log(四分位间距4.6 - 7.0)IU/mL,其中9名(17.6%)母亲的水平≥10IU/mL。80名(13.3%)母亲感染了HIV,其中9名(11.5%)同时感染了HBV。没有婴儿的HBsAg或HBVDNA检测呈阳性。
垂直传播似乎对乌干达北部地区高HBV流行率的影响不大。乌干达目前在婴儿6周龄时为其接种首剂乙肝疫苗的做法可能足以控制HBV传播。